Cite

    Richardson, P. et al. (2015). Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b–2 dose-escalation study. Lancet. 2 (12), pp. e516-e527. [Online].